Food and Drug Administration (2025) Compounding when drugs are on FDAs drug shortages list, U.S
Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain
I still haven't tried it but he was all about it for some reason
How to Mitigate Rising GLP-1 Medication Costs in Employer Healthcare Plans Key Takeaways: GLP-1 medications offer substantial long-term cost savings by reducing obesity-related complications
Its also relatively uncommon, occurring in less than 5% of people, based on available clinical data, and typically only affects hair on the scalp
in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk